Common use of NOTICE OF CONVERSION Clause in Contracts

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Convertible Note due February 26, 2020 of OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker No: __________________ Account No: _________________

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 108% Senior Convertible Note Debenture due February 26May 8, 2020 2021 of OncBioMune PharmaceuticalsSafe-T Group Ltd., Inc., a Nevada corporation an Israeli company (the “Company”), into shares of common stock ADSs (the “Common StockOrdinary Shares”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock Ordinary Shares and/or ADSs are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock Ordinary Shares and/or ADSs does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common StockADSs. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock ADSs __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock ADSs to be issued: Signature: Name: Address for Delivery of ADSs Certificates: Or DWAC Instructions: Broker No: __________________ Account No: _______________________________ Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Original Issue Discount Senior Secured Convertible Note Debenture due February 26September 13, 2020 2017 of OncBioMune Pharmaceuticals, Inc.Propanc Health Group Corp., a Nevada Delaware corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: __________________ Account No: _________________

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Original Issue Discount Senior Convertible Note Debenture due February 26September [__, 2020 of OncBioMune PharmaceuticalsLGBTQ LOYALTY HOLDINGS, Inc.INC., a Nevada Delaware corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: __________________ Account No: _________________

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 105% Senior Original Issue Discount Convertible Note Debenture due February 26______ __, 2020 2013 of OncBioMune PharmaceuticalsSpectrascience, Inc., a Nevada Minnesota corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account Accrued. Number of Conversion at Issue. Shares payable on Principal or Interest that would exceed the limits set forth in Section 4(c) of the Note: Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker No: __________________ Account No: _________________Address for Delivery of Common Stock Certificates Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert all or a portion of the principal under amount of that certain Convertible Debenture, dated May 7, 2015 (the 10% Senior Convertible Note due February 26“Debenture”), 2020 of OncBioMune Pharmaceuticalsissued by Sports Field Holdings, Inc., a Nevada corporation (the “Company”), in favor of the undersigned, due on February 1, 2015, and all accrued but unpaid interest thereon, unless previously repaid by the Company or converted into shares of common stock Private Placement Securities as provided in the Debenture (the “Common StockConversion Shares”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock the Conversion Shares are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder undersigned for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common StockConversion Shares. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker No: ___________________________________________________ Account NoPrincipal Amount of Debenture to be Converted: _________________________________ Accrued but Unpaid Interest to Date of Conversion: _________________________________ Number of Conversion Shares to be issued: _______________________________________ Signature: Name: Address:

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 108% Senior Unsecured Convertible Note Debenture due February 26November ___, 2020 2010 of OncBioMune Pharmaceuticals, Inc.Sona Mobile Holdings Corp., a Nevada Delaware corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common StockStock and will sell such shares of Common Stock pursuant to an effective Registration Statement and in accordance with the Transaction Documents within 5 Trading Days of receipt of said shares. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: __________________ Account No: __________________ Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal of the Loan under the 10% Senior Convertible Note due February 26Secured Term Loan Agreement dated January 30, 2020 of OncBioMune Pharmaceuticals2024 (the “Loan Agreement”) among Nauticus Robotics, Inc.Inc. (f/k/a Cleantech Acquisition Corp.), a Nevada Delaware corporation (the “Company”), ATW Special Situations Management LLC, as collateral agent, the lenders party thereto, into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. To be valid, this Notice of Conversion must be delivered to each of the following email addresses: Email: ********* Email: ********* Email: ********* Email: ********* By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Notethe Loan Agreement, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Loan to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $$ _____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: ____:______________ Account No: :__________________ ANNEX B DISQUALIFIED INSTITUTIONS

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 108% Original Issue Discount Senior Convertible Promissory Note due February 26October 11, 2020 2020, of OncBioMune PharmaceuticalsCreative Medical Technology Holdings, Inc., a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), ) of the Company according to the conditions hereof, hereof as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees Act (if applicable pursuant to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer provisions of Section 4 of the aforesaid shares of Common StockNote). Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: $ Payment of Interest in Common Stock __ Stock: yes __ no If yes, $_____ $ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker Name, address, contact person, arid telephone number: Broker DTC No: __________________ Account No: _________________Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert $_________________principal under amount of the 10% Senior Convertible Note due February 26(defined below) into that number of shares of Common Stock to be issued pursuant to the conversion of the Note (“Common Stock”) as set forth below, 2020 of OncBioMune PharmaceuticalsEVENTURE INTERACTIVE, Inc.INC., a Nevada corporation (the “CompanyBorrower”), into shares of common stock (the “Common Stock”), of the Company ) according to the conditions hereofof the convertible note of the Borrower dated as of June 25, 2015 (the “Note”), as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder Holder for any conversion, except for such transfer taxes, if any. By Box Checked as to applicable instructions: ¨ The Borrower shall electronically transmit the delivery of Common Stock issuable pursuant to this Notice of Conversion to the account of the undersigned represents and warrants to the Company that or its ownership nominee with DTC through its Deposit Withdrawal Agent Commission system (“DWAC Transfer”). Name of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. DTC Prime Broker: Account Number: ¨ The undersigned agrees to comply with hereby requests that the prospectus delivery requirements under Borrower issue a certificate or certificates for the applicable securities laws in connection with any transfer number of the aforesaid shares of Common Stock. Conversion calculationsStock set forth below (which numbers are based on the Holder’s calculation attached hereto) in the name(s) specified immediately below or, if additional space is necessary, on an attachment hereto: SBI Investments LLC, 2014-0 000 Xxxxxxxxx Xxxxxx, 0xx Xxxxx Xxx Xxxx, XX 00000 Attn: Xxxxx Xxxxxxxxxx Date to Effect of Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock _______________ yes __ no If yes, Applicable Conversion Price: $______________ of Interest Accrued on Account of Conversion at Issue. Number of shares Shares of Common Stock to be issuedIssued Pursuant to Conversion of the Notes: Signature_____________ Amount of Principal Balance Due remaining Under the Note after this conversion: Name: DWAC Instructions: Broker No______________ SBI INVESTMENTS LLC, 2014-1 By: __________________ Account No: __________________ Name: Xxxxx Xxxxxxxxxx Title: Manager, Sea Otter Global Investments, L.L.C. Date:

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10Original Issue Discount 5% Senior Convertible Note Debenture due February 26July __, 2020 2012 of OncBioMune PharmaceuticalsOriginOil, Inc., a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: __________________ Account No: __________________ Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Convertible Note due February 26May 24, 2020 2019 of OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker No: __________________ Account No: _________________

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Secured Convertible Note due February 26December 29, 2020 2023 of OncBioMune PharmaceuticalsEnsysce Biosciences, Inc., a Nevada Delaware corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No.: ____________________________ Account No.: __________________________

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 108.00% Senior Convertible Note convertible debenture due February 26December [🌑], 2020 2024 (the “Debenture”) of OncBioMune PharmaceuticalsPivotal Acquisition Corp. (to be renamed KLDiscovery, Inc.), a Nevada Delaware corporation (the “Company”), held by it into shares of Class A common stock stock, par value $0.0001 per share, of the Company (the “Common Stock”), of the Company ) according to the conditions hereofcontained in the Debenture, as of the date written below. Capitalized terms used herein and not otherwise defined shall have the meanings assigned to them in the Debenture. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as required by the Debenture and the Purchase Agreement and as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Information: Conversion calculations: Date to Effect ConversionDate: Principal Amount of Note to be ConvertedDebenture: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares Shares of Common Stock to be issuedBe Issued: Signature: Name: Address for Delivery of Common Stock Certificates: or DWAC Instructions: Broker No: Account No: EXHIBIT B FORM OF NON-BANK CERTIFICATE To: Pivotal Acquisition Corp. (to be renamed KLDiscovery, Inc.) (the “Company”) From: [_____] (the “Purchaser”) Dated: [_____________ Account No: _________________] We refer to the securities purchase agreement, dated December 16, 2019 (the “Agreement”). For purposes of Section 4.1(a)(ii)(3) of the Agreement, the Purchaser hereby certifies that it is not:

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 105% Senior Original Issue Discount Convertible Promissory Note due February 26December __, 2020 2017 of OncBioMune PharmaceuticalsDirectView, Inc., a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker No: __________________ Account No: __________________ Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Convertible Note due February 263, 2020 of OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker No: __________________ Account No: _________________

NOTICE OF CONVERSION. The undersigned hereby elects to convert $__________ principal under the 10% Senior Convertible Note due February 26, 2020 Debenture of OncBioMune Pharmaceuticals, WaveRider Communications Inc., a Nevada corporation (the “"Company”"), due on November 12, 2007, into shares of common stock stock, par value $0.001 per share (the “"Common Stock”"), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act, specified under Section 4 of this Debenture. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest Holder Holder is exercising Conditional Redemption Right ________(yes/no) Conditional Redemption Price (in Common Stock accordance with current Company Election): $ __ yes __ no If yes, $______ of Interest Accrued on Account of And/or Conversion at Issue. Number of shares of Common Stock Shares to be issued: ________ at a conversion price of: $ ________ Conversion Date: ________ The Shares are to be issued in the name of _______________________., and stock certificates representing such Shares are to be delivered to: in accordance with the Transfer Agent Instructions, dated April ____, 2004, delivered by the Company to Corporate Stock Transfer Inc. Holder Signature: Name: DWAC Instructions: Broker No: __________________ Account No: _________________________________________ Company The Company confirms acceptance of this Notice of Conversion (To be faxed to _______________________________________________within 1 Trading Day of receipt by the Company).

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Secured Convertible Note due February 26July 19, 2020 2023 of OncBioMune PharmaceuticalsCenntro Electric Group Limited ACN 619 054 938, Inc., a Nevada corporation an Australian public company (the “Company”), into ordinary shares of common stock (the “Common StockOrdinary Shares”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock Ordinary Shares are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock Ordinary Shares does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange ActAct and reconfirms the representations and warranties provided by it in Section 3.2(c), 3.2(i), 3.2(j) and 3.2(k) of the Purchase Agreement. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common StockOrdinary Shares. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock Ordinary Shares __ yes __ no If yes, $US$_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock Ordinary Shares to be issued: Signature: Name: Address for Delivery of Ordinary Shares Certificates: Or DWAC Instructions: Broker No: __________________ Account No: _________________.:

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 108% Senior Secured Convertible Note Debenture due February 26_______________, 2020 2023 of OncBioMune Pharmaceuticals, Inc.Ucommune International Ltd, a Nevada corporation Cayman Islands exempted company (the “Company”), into shares Ordinary Shares of common stock the Company (the “Common StockOrdinary Shares”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock Ordinary Shares are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock Ordinary Shares does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common StockOrdinary Shares. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: __________________ Account No: _________________:

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10Second Amended and Restated 2.5% Senior Secured Convertible Note due February 26May 12, 2020 2014 (the “Note”) of OncBioMune Pharmaceuticals, AtheroNova Inc., a Nevada Delaware corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this the Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common StockStock pursuant to any prospectus. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. : Number of shares of Common Stock to be issued: issued (not less than 10,000 shares): Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: __________________ Account No: _________________:

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Convertible Note due February 26Promissory Note, 2020 with an issue date of OncBioMune PharmaceuticalsOctober 7, Inc.2022, a Nevada corporation of Creatd Inc. (the “Company”), ) into shares of common stock stock, par value $0.001 per share (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company Companies in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company Companies that its ownership of the Common Stock does not exceed the amounts specified under Section 4 5 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker No: :_____________________________ Account No: Name:________________________________ Delivery Instructions:

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 1016% Senior Secured Convertible Note Debenture due February 26June 27, 2020 2014 of OncBioMune PharmaceuticalsGenius Brands International, Inc., a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The If there shall be an effective Registration Statement, the undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: _:_________________ Account No: :__________________ Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 108% Senior Secured Convertible Note Debenture due February 26March 30, 2020 2018 of OncBioMune PharmaceuticalsDigital Ally, Inc., a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: _:_________________ Account No: :_______________ Schedule 1 CONVERSION SCHEDULE The 8% Senior Secured Convertible Debentures due on March 30, 2018 in the aggregate principal amount of $________ are issued by Digital Ally, Inc., a Nevada corporation. This Conversion Schedule reflects conversions made under Section 4 of the above referenced Debenture. Dated: Date of Conversion (or for first entry, Original Issue Date) Amount of Conversion Aggregate Principal Amount Remaining Subsequent to Conversion (or original Principal Amount) Company Attest

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Original Issue Discount Senior Convertible Note Debenture due February 26March 1, 2020 2018 of OncBioMune PharmaceuticalsLegend Oil and Gas, Inc.Ltd., a Nevada Colorado corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: :__________________ Account No: :__________________ Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Original Issue Discount Senior Secured Convertible Note Debenture due February 26October 1, 2020 2017 of OncBioMune PharmaceuticalsPFO Global, Inc., a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: __________________ Account No: _________________Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 109% Senior Secured Convertible Note Debenture due February 26June 14, 2020 2023 of OncBioMune Pharmaceuticals, Inc.Lion Group Holding Ltd., a Nevada corporation Cayman Islands exempted company (the “Company”), into shares of common stock American Depository Shares (the “Common StockADSs”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock ADSs are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock ADSs does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common StockADSs. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock ADSs __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock ADSs to be issued: Signature: Name: Address for Delivery of ADSs Certificates: Or DWAC Instructions: Broker No: _____:_____________ Account No: :_________________

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Original Issue Discount Senior Convertible Note Debenture due February 26March 1, 2020 2018 of OncBioMune PharmaceuticalsLegend Oil and Gas, Inc.Ltd., a Nevada Colorado corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: ___________________ Account No: __________________ Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Original Issue Discount Senior Convertible Note due February 2613, 2020 of OncBioMune PharmaceuticalsQUAD M SOLUTIONS, Inc.INC., a Nevada an Idaho corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 4(d) of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker No: :__________ Account No:__________ Exhibit B Affidavit of Confession of Judgment Immediately Follows Affidavit of Confession of Judgment SUPREME COURT OF THE STATE OF NEW YORKCOUNTY OF NEW YORK Index No. __________________________ Account NoPlaintiff, -against- AFFIDAVIT OF CONFESSION OF JUDGMENT QUAD M SOLUTIONS, INC. Defendant. X STATE OF NEW JERSEY ) ) ss.: _________________COUNTY OF ESSEX ) Xxxxxxxx Xxxxx, being duly sworn, hereby deposes and says:

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal and interest under the 1015% Senior OID Convertible Note Promissory Notes due February 26April 5, 2020 2022 of OncBioMune PharmaceuticalsmPhase Technologies, Inc., a Nevada corporation Inc. (the “Company”), into shares of its common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: ____________________________________________ Principal Amount of Note to be Converted: ______________________________ Payment of Interest in Common Stock ___ yes ___ no If yes, $_____ ____of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker No: __________________ Account NoSignature Name Delivery Instructions: _________________Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal amounts outstanding under the 10% Senior Secured Convertible Note due February 26, 2020 Debenture of OncBioMune PharmaceuticalsAmergent Hospitality Group, Inc., a Nevada Delaware corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder Holders for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker No: _______________________________________ Account No(if not date is set, conversion date shall be the date this notice is received) Amount of Debenture to be Converted: $________________________ Signature: Name: Address: EXHIBIT B ASSIGNMENT FORM (To assign the foregoing Debenture, execute this form and supply required information. Do not use this form to purchase shares.) FOR VALUE RECEIVED, the foregoing Debenture and all rights evidenced thereby are hereby assigned to Name: (Please Print) Address: (Please Print) Phone Number: Email Address: Dated: ___________________________, ________ Holder’s Signature: Address: REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of April 1, 2020 by and among Amergent Hospitality Group, Inc. a Delaware corporation (the “Company”), each of parties on the signature page hereto. Each of the parties on the signature page hereto, including Arena (as defined below) and any person or entity who hereafter becomes a party to this Agreement pursuant to Section 5.02 of this Agreement, is herein referred to as a “Holder” and collectively as the “Holders”.

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Original Issue Discount Convertible Note Debenture due February 26May 2, 2020 2017 of OncBioMune PharmaceuticalsRennova Health, Inc., a Nevada Delaware corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Price: Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: _:_________________ Account No: __________________ Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Convertible Note due February 26________ ___, 2020 of OncBioMune Pharmaceuticals2018 issued by Guided Therapeutics, Inc., a Nevada Delaware corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker No: _____________________________ Account No: _____________________________________ Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 105% Senior Original Issue Discount Convertible Note Debenture due February 26September __, 2020 2014 of OncBioMune PharmaceuticalsSpectrascience, Inc., a Nevada Minnesota corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account Accrued. Number of Conversion at Issue. Shares payable on Principal or Interest that would exceed the limits set forth in Section 4(c) of the Note: Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker NoAddress for Delivery of Common Stock Certificates: __________________ Account No: __________________ Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Convertible Note due February 26, 2020 _______________________ of OncBioMune Pharmaceuticals, Inc.ADAMIS PHARMACEUTICALS CORPORATION, a Nevada Delaware corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the issuance shall comply with the transfer restrictions in the Purchaser Agreement and the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common StockStock pursuant to any prospectus. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. : Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or: DWAC Instructions: Broker No: __________________ Account No: _________________:

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 106% Senior Secured Convertible Note (the “Note”) due February 26April 15, 2020 2015 of OncBioMune PharmaceuticalsGrowLife, Inc. (formerly Phototron Holdings, Inc.), a Nevada Delaware corporation (the “Company”), into shares of common stock (the “Common Stock”), ) of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion Conversion, the undersigned represents and warrants to the Company that (check one): ________ its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. ________ immediately prior to giving effect to this Notice of Conversion, it owns more than 9.9% of the outstanding shares of Common Stock, as determined in accordance with Section 4 of the Note. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common StockStock pursuant to any prospectus. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. : Number of shares of Common Stock to be issued: issued (not less than an amount equal to the greater of (A) $35,000 of the Principal Amount the Note and any accrued but unpaid interest thereon and (B) 5,000,000 shares): Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: __________________ Account No: _________________ANNEX B

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 108% Original Issue Discount Senior Convertible Note Debenture due February 26September ___, 2020 2014 of OncBioMune PharmaceuticalsAmarantus BioScience Holdings, Inc., a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: __________________ Account No: __________________ Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 1013.25% Senior Secured Convertible Note due February 26September 24, 2020 of OncBioMune Pharmaceuticalsissued by Medite Cancer Diagnostics, Inc., a Nevada Delaware corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Cash Interest in Common Stock __ yes __ no If yes, $_____ of Cash Interest Accrued on Account of Conversion at Issueissue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker No: __________________ Account No: _________________Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Original Issue Discount Convertible Note Debenture due February 26October 5, 2020 2019 of OncBioMune Pharmaceuticals, Inc.MMEX Resources Corporation, a Nevada corporation (the “Company”), into shares of Class A common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ __of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker No: __:________________ Account No: :__________________ Schedule 1

NOTICE OF CONVERSION. (To be Executed by the Registered Holder in order to convert shares of Preferred Stock) The undersigned hereby elects to convert principal under the 10% Senior number of shares of Series E Convertible Note due February 26Preferred Stock indicated below, 2020 into shares of OncBioMune Pharmaceuticalscommon stock, par value $.00001 per share (the “Common Stock”), of BioNeutral Group, Inc., a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder Holder for any conversion, except for such transfer taxes, if any. By the delivery of tendering this Notice of Conversion Conversion, the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees hereby covenants to comply with the prospectus delivery requirements under the Securities Act of 1933, as amended, applicable securities laws in connection to it with any transfer respect to resales of the aforesaid shares of Common StockStock issuable upon the conversion requested hereby pursuant to a registration statement and, in connection therewith, covenants that, unless otherwise specified below, such shares have been or are intended to be sold in ordinary brokerage transactions. Conversion calculations: Date to Effect Conversion: Principal Amount Conversion Number of Note shares of Preferred Stock owned prior to Conversion Number of shares of Preferred Stock to be Converted: Payment Converted Stated Value of Interest in Common shares of Preferred Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. to be Converted Number of shares of Common Stock to be issuedIssued Applicable Conversion Price Number of shares of Preferred Stock subsequent to Conversion Signature Name Address Accepted and Agreed: Signature: Name: DWAC Instructions: Broker No: BioNeutral Group, Inc. By:_____________________________________ Account NoName: _________________Title:

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Original Issue Discount Convertible Note Debenture due February 26May 14, 2020 2012 of OncBioMune PharmaceuticalsOctavian Global Technologies, Inc., a Nevada Delaware corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: ______________________ Account No: ____________________ Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert all or a portion of the principal under amount of that certain Convertible Debenture, dated May [●], 2015 (the 10% Senior Convertible Note due February 26“Debenture”), 2020 of OncBioMune Pharmaceuticalsissued by MamaMancini’s Holdings, Inc., a Nevada corporation (the “Company”), in favor of the undersigned, due on July [●], 2016, and all accrued but unpaid interest thereon, unless previously repaid by the Company or converted into shares of common stock Private Placement Securities as provided in the Debenture (the “Common StockConversion Shares”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock the Conversion Shares are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder undersigned for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common StockConversion Shares. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker No: ___________________________________________________ Account NoPrincipal Amount of Debenture to be Converted: _________________________________ Accrued but Unpaid Interest to Date of Conversion: _________________________________ Number of Conversion Shares to be issued: _______________________________________ Signature: Name: Address:

NOTICE OF CONVERSION. The undersigned hereby elects to convert the principal under the 10% Senior Secured Convertible Promissory Note due February 26[●], 2020 2025 (the “Note”) of OncBioMune PharmaceuticalsRxxx’x, Inc.Inc, a Nevada Delaware corporation (the “CompanyBorrower”), into shares of common stock stock, par value $0.0001 per share (the “Common Stock”), of the Company Borrower according to the conditions hereof, as of the date written below. If shares of Common Stock are Capitalized terms used but not otherwise defined herein shall have the meanings assigned to be issued such terms in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if anyNotes. By the delivery of this Notice of Conversion Conversion, except as otherwise noted below, the undersigned represents and warrants to the Company Borrower that its ownership of the Common Stock issuable in connection with this conversion does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d5(b) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common StockNote. Conversion calculations: Date to Effect ConversionDate: Principal Amount of Note to be Converted: Payment DTC Account Delivery Instructions: Wire Instructions (for cash payments): Other Matters: Updated Conversion/PIK Schedule Attached. [______________] By: Name: Title: Dated: ANNEX B ACKNOWLEDGMENT OF CONVERSION Reference is made to the Secured Convertible Promissory Notes due [●], 2025 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Notes”), issued by Rxxx’x, Inc., a Delaware corporation (the “Borrower”), and Wilmington Savings Fund Society, FSB, as holder representative and collateral agent. Capitalized terms used but not otherwise defined herein shall have the meanings assigned to such terms in the Notes. The Borrower hereby (a) acknowledges the Notice of Interest in Conversion dated [___], (b) certifies that the shares of Common Stock [are][are not] eligible to be resold by the Holder either (i) pursuant to Rule 144 (subject to the Holder’s execution and delivery to the Borrower of a customary Rule 144 representation letter) or (ii) an effective and available registration statement covering such shares of Common Stock and (c) hereby directs __ yes __ no If yes, $_______________ of Interest Accrued on Account of Conversion at Issue. Number to issue the above indicated number of shares of Common Stock in accordance with the Transfer Agent Instructions dated _____________, 20__ from the Borrower and acknowledged and agreed to be issued: Signatureby ________________________. RXXX’X, INC., as Borrower a Delaware corporation By: Name: DWAC InstructionsTitle: Broker ANNEX C FUNDAMENTAL CHANGE REPURCHASE NOTICE RXXX’X INC. 10.00% Secured Convertible Promissory Notes due 2025 Subject to the terms of the Notes, by executing and delivering this Fundamental Change Repurchase Notice, the undersigned Holder of the Note identified below is exercising its Fundamental Change Repurchase Right with respect to (check one): ☐ the entire principal amount of ☐ $ ____________* aggregate principal amount of the Note identified by Certificate No: . _______________. The undersigned acknowledges that this Note, duly endorsed for transfer, must be delivered to the Paying Agent before the Fundamental Change Repurchase Price will be paid. Date:_________________________________________ Account No(Legal Name of Holder) By: _________________Name: Title:

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 105% Senior Original Issue Discount Convertible Note Debenture due February 26July 27, 2020 2012 of OncBioMune PharmaceuticalsSpectrascience, Inc., a Nevada Minnesota corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account Accrued. Number of Conversion at Issue. Shares payable on Principal or Interest that would exceed the limits set forth in Section 4(c) of the Note: Number of shares of Common Stock to be issued: Signature: Name: DWAC InstructionsAddress for Delivery of Common Stock Certificates: Broker No: __________________ Account No: _________________Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Secured Convertible Note due February 26June 8, 2020 2022 of OncBioMune Pharmaceuticals, Allied Esports Entertainment Inc., a Nevada Delaware corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: ____________________ Account No: ____________________

NOTICE OF CONVERSION. (To be Executed by the Registered Holder in order to convert the Series A Preferred Stock) The undersigned hereby irrevocably elects to convert principal under the 10% Senior Convertible Note due February 26, 2020 covert ___________ shares of OncBioMune Pharmaceuticals, Inc., a Nevada corporation Series A Preferred Stock (the “CompanyConversion”), represented by Stock Certificate No(s). ________ (the “preferred Stock Certificates”), into shares of common stock (the “Common Stock”)) of iVoice, of Inc. (the Company “Corporation”) according to the conditions hereofof the Certificates of Designations, Preferences and Rights of Series A Convertible Preferred Stock (the “Certificate of Designation”), as of the date written below. If shares of Common Stock securities are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewiththereto. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By Each Preferred Stock Certificate is attached hereto (or evidence or loss, theft or destruction thereof). Except as may be provided below, the delivery of Corporation shall electronically transmit the Common Stock issuable pursuant to this Notice of Conversion to the account of the undersigned represents or its nominee (which is ___________ ) with DTC through its Deposit Withdrawal Agent Commission System (“DTC Transfer”). In the event of partial exercise, please reissue a new stock certificate for the number of shares of Series A Preferred Stock which shall not have been converted. The undersigned acknowledges and warrants agrees that all offers and sales by the undersigned of the securities issuable to the Company that its ownership undersigned upon conversion of the Series A Preferred Stock have been or will be made only pursuant to an effective registration of the transfer of the Common Stock does not exceed under the amounts specified under Section 4 Securities Act of this Note1933, as determined in accordance with Section 13(d) of amended (the Exchange “Act”), or pursuant to an exemption from registration under the Act. The In lieu of receiving the shares of Common Stock issuable pursuant to this Notice of Conversion by way of DTC Transfer, the undersigned agrees hereby request that the Corporation issue and deliver to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid undersigned physical certificates representing such shares of Common Stock. Conversion calculations: Date to Effect of Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker No: ________________________________ Account NoNumber of Shares Converted: _________________________ Signature: ________________________________________ Name: ____________________________________________ Address: __________________________________________ Exhibit C ADMINISTRATIVE SERVICES AGREEMENT This Administrative Services Agreement (the “Agreement”) is entered March 10, 2011 by and between B Green Innovations, Inc., a New Jersey corporation, with its principal office at 000 Xxxxx 00, Xxxxxxx, XX, 00000 (“B Green”), and iVoice, Inc., a New Jersey corporation, with its principal office at 000 Xxxxx 00, Xxxxxxx, XX, 00000 (the “Company”).

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 105% Senior Convertible Note Debenture due February 26November 25, 2020 2009, of OncBioMune PharmaceuticalsGlobal Roaming Distribution, Inc., a Nevada Florida corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: __________________ Account No: _________________

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Secured Convertible Note Promissory Note, due February 26January 1, 2020 2019 of OncBioMune PharmaceuticalsDPW Holdings, Inc., a Nevada Delaware corporation (the “Company”), into shares of common stock of the Company (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion Conversion, the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes Yes __ no No If yesYes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares Shares of Common Stock to be issuedIssued: Signature: Name: DWAC Delivery Instructions: Broker No: __________________ Account No: _________________:

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 108% Original Issue Discount Senior Secured Convertible Note Debenture due February 26December 1, 2020 2014 of OncBioMune PharmaceuticalsBOLDFACE Group, Inc., a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the of applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: __________________ Account No: _________________Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 1012% Senior Unsecured Subordinated Convertible Note Debenture due February 26November 30, 2020 2022 of OncBioMune PharmaceuticalsSmart for Life, Inc., a Nevada Delaware corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: ___:_______________ Account No: :_________________

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 106% Senior Convertible Note Debenture due February 26, 2020 2018 of OncBioMune PharmaceuticalsBoston Therapeutics, Inc., a Nevada Delaware corporation (the “"Company”"), into shares of common stock (the “"Common Stock”"), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: __________________ Account No: _________________Schedule 1

NOTICE OF CONVERSION. To: [Name of Bank], As Conversion Agent Citizens Utilities Capital L.P. The undersigned owner of these Partnership Preferred Securities hereby elects irrevocably exercises the option to convert principal under these Partnership Preferred Securities, or the 10% Senior Convertible Note due February 26, 2020 of OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”)portion below designated, into shares of common stock Common Stock, Series A, par value $.25 per share, of CITIZENS UTILITIES COMPANY ("Common Stock") in accordance with the terms of the Amended and Restated Agreement of Limited Partnership (the “Common Stock”"Limited Partnership Agreement"), dated as of _________ ___, 1995, by and among Citizens Utilities Company, as the general partner, ____________, as initial limited partner, and such other Persons (as defined therein) who become Limited Partners (as defined therein) as provided in the Limited Partnership Agreement. Pursuant to the aforementioned exercise of the Company according option to convert these Partnership Preferred Securities, the undersigned hereby directs the Conversion Agent (as that term is defined in the Limited Partnership Agreement) to (i) exchange such Partnership Preferred Securities for a portion of the Convertible Debentures (as that term is defined in the Limited Partnership Agreement) held by the Limited Partnership (as such term is defined in the Limited Partnership Agreement) (at the rate of exchange specified in the Limited Partnership Agreement) and (ii) immediately convert such Convertible Debentures on behalf of the undersigned, into Common Stock (at the conversion rate specified in the Limited Partnership Agreement). The undersigned does also hereby direct the Conversion Agent that the shares issuable and deliverable upon conversion, together with any check in payment for fractional shares, be issued in the name of and delivered to the conditions hereofundersigned, as of unless a different name has been indicated in the date written assignment below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewiththereto. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this This Notice of Conversion and any action taken hereunder shall be governed by the undersigned represents and warrants to the Company that its ownership terms of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange ActLimited Partnership Agreement. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculationsDate: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $____________, ____ of Interest Accrued on Account of Conversion at Issue. in whole __ in part Number of shares of Common Stock Partnership Preferred Securities to be issued: Signature: Name: DWAC Instructions: Broker Noconverted: ___________________ Account NoIf a name or names other than the undersigned, please indicate in the spaces below the name or names in which the shares of Common Stock are to be issued, along with the address or addresses of such person or persons Signature (for conversion only) Please Print or Typewrite Name and Address, Including Zip Code, and Social Security or Other Identifying Number ANNEX B NOTICE OF DISTRIBUTION ELECTION TO: _________________, As Election Agent Citizens Utilities Capital L.P. The undersigned owner of ____% Convertible Partnership Preferred Securities (liquidation preference $50 per preferred security) (the "Partnership Preferred Securities"), issued pursuant to the Amended and Restated Agreement of Limited Partnership (the "Limited Partnership Agreement"), dated as of ___________ ___, 1995, by and among Citizens Utilities Company, as the general partner, ____________, as initial limited partner, and such other Persons (as defined therein) who become Limited Partners (as defined therein) as provided in the Limited Partnership Agreement, hereby irrevocably elects to receive, in the form prescribed below, Distributions (as such term is defined in the Limited Partnership Agreement) due and payable to the undersigned on the four Distribution Payment Dates (as such term is defined in the Limited Partnership Agreement) occurring after the Election Period during which this Notice of Distribution Election is being submitted. The Undersigned, as Holder of [NUMBER OF PARTNERSHIP PREFERRED SECURITIES HELD] Partnership Preferred Securities, elects to receive payment of Distributions due and payable on the next four Distribution Payment Dates in the form: Choose one:

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Convertible Third Amended and Restated Secured Bridge Note due February 26June 30, 2020 2015 Number 2014-1 of OncBioMune PharmaceuticalsENVISION SOLAR INTERNATIONAL, Inc.INC., a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts limitation specified under Section 4 of this NoteNote (if any), as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common StockStock pursuant to any prospectus. Conversion calculations: Date to Effect Conversion: ______________ Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $____________ of Interest Accrued on Account of Conversion at Issue. : ______________ Number of shares of Common Stock to be issued: SignatureGEMINI MASTER FUND, LTD. By: GEMINI STRATEGIES LLC, INC., as investment manager By: ______________ ______________ Name: Xxxxxx Xxxxxxx Title: President Name: GEMINI MASTER FUND, LTD. Address for Delivery of Common Stock Certificates: ____________________________ ____________________________ Or DWAC Instructions: Broker No: __________________ Account No: _________________

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Amended and Restated Convertible Note due February 26December 31, 2020 2024 of OncBioMune PharmaceuticalsVivakor, Inc., a company incorporated under the law of Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Amended Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $______________ Principal and/or Interest Amount of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock Amended Note to be issued: Signature: Name: DWAC Instructions: Broker NoConverted: __________________ Account NoNumber of shares of Common Stock to be issued: ________________ Signature: Name: Address for Delivery of Common Stock Certificates: ________________ Or DWAC Instructions: Broker No: Account No:

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 108% Original Issue Discount Senior Convertible Note Debenture due February 26September ___, 2020 2014 of OncBioMune PharmaceuticalsAmarantus BioScience Holdings, Inc., a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: _______:___________ Account No: :__________________ Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal and interest under the 1015% Senior OID Convertible Note Promissory Notes due February 26March 8, 2020 2022 of OncBioMune PharmaceuticalsSurgePays, Inc., a Nevada corporation Inc. (the “Company”), into shares of its common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: ____________________________________ Principal Amount of Note to be Converted: _______________________ Payment of Interest in Common Stock __ yes __ no If yes, $_____ __of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker No: __________________ Account NoSignature Name Delivery Instructions: _________________Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Original Issue Discount Convertible Note Promissory Note, due February 26June 28, 2020 2017 of OncBioMune PharmaceuticalsGuided Therapeutics, Inc., a Nevada Delaware corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Delivery Instructions: Broker No: __________________ Account No: _________________Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 108% Original Issue Discount Senior Secured Convertible Note Debenture due February 26August 1, 2020 2015 of OncBioMune PharmaceuticalsBOLDFACE Group, Inc., a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the of applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: :________________________ Account No: :______________________ Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Convertible Note due February 26September 29, 2020 2018 of OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker No: ___________________ Account No: __________________

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Convertible Note due February 26November ____, 2020 2018 of OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker No: __:________________ Account No: :_________________

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 108% Senior Secured Convertible Note due February 26September 4, 2020 2019, of OncBioMune PharmaceuticalsShiftPixy, Inc., a Nevada Wyoming corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: __________________ Account No: _________________Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Convertible Note due February June 26, 2020 2024 of OncBioMune Pharmaceuticals, Bruush Oral Care Inc., a Nevada corporation company incorporated under the law of British Columbia, Canada (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: ________ Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_________ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: _______ Signature: ________________ Name: _________________ Address for Delivery of Common Stock Certificates: ____________________ Or DWAC Instructions: Broker No: __________________ Account No: _________________

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Original Issue Discount Senior Secured Convertible Note Debenture due February 26March 1, 2020 2017 of OncBioMune PharmaceuticalsLegend Oil and Gas, Inc.Ltd., a Nevada Colorado corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: __________________ Account No: __________________ Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Convertible Note due February 26May 25, 2020 of OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker No: __________________ Account No: _________________

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 106% Senior Secured Convertible Note (the “Note”) due February 26April 15, 2020 2015 of OncBioMune PharmaceuticalsPhototron Holdings, Inc., a Nevada Delaware corporation (the “Company”), into shares of common stock (the “Common Stock”), ) of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion Conversion, the undersigned represents and warrants to the Company that (check one): ________ its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. ________ immediately prior to giving effect to this Notice of Conversion, it owns more than 9.9% of the outstanding shares of Common Stock, as determined in accordance with Section 4 of the Note. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common StockStock pursuant to any prospectus. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. : Number of shares of Common Stock to be issued: issued (not less than an amount equal to the greater of (A) $35,000 of the Principal Amount the Note and any accrued but unpaid interest thereon and (B) 100,000 shares): Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: __________________ Account No: _________________:

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 106% Senior Convertible Note Debenture due February 26October ___, 2020 2012, of OncBioMune PharmaceuticalsInnovative Card Technologies, Inc., a Nevada Delaware corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: _:_________________ Account No: :_________________

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 1020% Senior Original Issue Discount Convertible Note Debenture due February 26[_______, 2020 2016] of OncBioMune PharmaceuticalsProtea Biosciences Group, Inc., a Nevada Delaware corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ ¨ yes __ ¨ no If yes, $_____ of Interest Accrued on Account Accrued. Number of Conversion at Issue. Shares payable on Principal or Interest that would exceed the limits set forth in Section 4(c) of the Note: Number of shares of Common Stock to be issued: Signature: Name: DWAC InstructionsAddress for Delivery of Common Stock Certificates: Broker No: __________________ Account No: _________________Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 1012% Senior Secured Convertible Note (the “Note”) due February 26June 8, 2020 2015 of OncBioMune PharmaceuticalsGrowLife, Inc., a Nevada Delaware corporation (the “Company”), into shares of common stock (the “Common Stock”), ) of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion Conversion, the undersigned represents and warrants to the Company that (check one): ________ its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. ________ immediately prior to giving effect to this Notice of Conversion, it owns more than 9.9% of the outstanding shares of Common Stock, as determined in accordance with Section 4 of the Note. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common StockStock pursuant to any prospectus. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. : Number of shares of Common Stock to be issued: issued (not less than $10,000.00 of the Principal Amount ): Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: __________________ Account No: _________________:

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 108% Senior Convertible Note Debenture due February 26September __, 2020 of OncBioMune PharmaceuticalsSafe-T Group Ltd., Inc., a Nevada corporation an Israeli company (the “Company”), into shares of common stock ADSs (the “Common StockOrdinary Shares”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock Ordinary Shares and/or ADSs are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock Ordinary Shares and/or ADSs does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common StockADSs. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock ADSs __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock ADSs to be issued: Signature: Name: Address for Delivery of ADSs Certificates: Or DWAC Instructions: Broker No: __________________ Account No: _________________Schedule 1

NOTICE OF CONVERSION. The undersigned holder of this Receipt for Depositary Shares (the "Depositary Shares") hereby elects irrevocably exercises the option to convert principal under the 10% Senior Convertible Note due February 26, 2020 of OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), _______ Depositary Shares evidenced thereby into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock (and any other applicable securities or property) of the Company in accordance with the terms and conditions of the Deposit Agreement, dated as of _______, 199_, among the Company, ___________________________, as Depositary, and the holders from time to time of Receipts referred to in such Deposit Agreement, and directs that certificates for the securities deliverable upon such conversion be registered in the name of and delivered, together with a check in payment for any fractional shares and any other property deliverable upon which conversion to the undersigned unless a different name has been indicated below. If securities are to be issued registered in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and thereto. If the number of Depositary Shares indicated above is delivering herewith such certificates and opinions as reasonably requested less than the number of Depositary Shares evidenced by this Receipt, the Company in accordance therewith. No fee will be charged undersigned directs the Depositary to issue to the holder for any conversionundersigned, except for such transfer taxesunless a different name is indicated below, if anya new Receipt evidencing the Depositary Shares not so converted. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker NoDated: __________________ Account NoSignature ------------------------------ NOTE: The signature(s) to this assignment must correspond with the name(s) as written upon the face of the Receipt in every particular, without alteration or enlargement, or any change whatever. (Please print name and address of registered holder) Name _______________________________________________________ Taxpayer Identification Number _____________________________ Address ____________________________________________________ (Please indicate other delivery instructions, if applicable)

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% third amendment to, which constitutes an amendment and restatement in full of, that certain $550,000.00 Senior Convertible Note due February 26Secured, 2020 Convertible, Redeemable Debenture, initially dated as of OncBioMune PharmaceuticalsDecember 31, Inc.2012, effectively issued as of January 16, 2013, and as amended and restated in full on December 1, 2014, of PositiveID Corporation, a Nevada Delaware corporation (the “Company”), into shares of common stock (the “Common Stock”), ) of the Company according to the conditions hereof, hereof as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: , 201___ Principal Amount of Note to be Converted: $ Payment of Interest in Common Stock __ Stock: ☐ yes __ ☐ no If yes, $_____ $ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker Name, address, contact person, and telephone number: Broker DTC No: _________________________________________________________ Account No: __________________________________________________________ Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Convertible Note due February 26May 24, 2020 2019 of OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker No: __________________ Account No: _________________:

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal certain amounts owed under the 10% Senior Original Issue Discount Secured Convertible Note Debenture due February 26October [___], 2020 20215 of OncBioMune Pharmaceuticals, Inc.Greenbox POS, a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment Interest Amount of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Debenture to be Converted: Number of shares of Common Stock to be issued: Conversion Price: Principal Remaining: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: __________________ Account No: _________________:

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 108% Original Issue Discount Senior Secured Convertible Note Debenture due February 26, 2020 ________ of OncBioMune PharmaceuticalsInspireMD, Inc., a Nevada Delaware corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment Accrued and Unpaid Interest Amount of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Debenture to be Converted Conversion at Issue. Adjustment Amount to be Converted Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: :_________________________ Account No: :_______________________ Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Original Issue Discount Senior Convertible Note Debenture due February 26March 1, 2020 2018 of OncBioMune PharmaceuticalsLegend Oil and Gas, Inc.Ltd., a Nevada Colorado corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: __________________ Account No: __________________ Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 108% Senior Secured Convertible Note due February 26September 4, 2020 2019, of OncBioMune PharmaceuticalsShiftPixy, Inc., a Nevada Wyoming corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: __________________ Account No: _________________29 Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Convertible Note Debenture due February 26________, 2020 2046 of OncBioMune PharmaceuticalsRosetta Genomics Ltd., Inc., a Nevada an Israeli corporation (the “Company”), into Ordinary shares of common stock (the “Common StockOrdinary Shares”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock Ordinary Shares are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does Ordinary Shares do not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange ActAct and that he complies with all the representations and warranties detailed in Section 3.2(c) of the Purchase Agreement. Without derogating from the above, the Holder acknowledge and agrees that in the event that following issuance of the Conversion Shares he will hold 5% or more of the issued share capital of the Company, the issuance of the Conversion Shares shall be require the delivery by the Holder to the Company of an executed Undertaking towards the NTIA (as such terms are defined in the Purchase Agreement) substantially in the form that was attached to the Purchase Agreement as Exhibit B or in any other form required by the NTIA within 3 Trading Days following the delivery of this Notice of Conversion. [In this regard the undersigned represents that following the issuance of the Conversion Shares it will not hold 5% or more of the issued share capital of the Company.] The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common StockOrdinary Shares. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock Ordinary Shares to be issued: Signature: Name: DWAC Instructions: Broker No: Account No: Schedule 1 CONVERSION SCHEDULE The Convertible Debentures due on ________, 2046 in the aggregate principal amount of $____________ Account Noare issued by Rosetta Genomics Ltd., an Israeli corporation. This Conversion Schedule reflects conversions made under Section 4 of the above referenced Debenture. Dated: _________________Date of Conversion (or for first entry, Original Issue Date) Amount of Conversion Aggregate Principal Amount Remaining Subsequent to Conversion (or original Principal Amount) Company Attest

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Convertible Note due February 26Promissory Note, 2020 with an issue date of OncBioMune PharmaceuticalsOctober 7, Inc.2022, a Nevada corporation of Creatd Inc. (the “Company”), ) into shares of common stock stock, par value $0.001 per share (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company Companies in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company Companies that its ownership of the Common Stock does not exceed the amounts specified under Section 4 5 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker No: :_____________________________ Account No: Name:________________________________ Delivery Instructions: ANNEX A Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Original Issue Discount Convertible Note Debenture due February 26May 9, 2020 2018 of OncBioMune PharmaceuticalsTHE Therapeutics, Inc., a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Price: Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker No: ___________________ Account No: __________________ Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 108% Original Issue Discount Senior Secured Convertible Note Debenture due February 26August 9, 2020 2018 of OncBioMune Pharmaceuticals, Inc.Sysorex Global, a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: :__________________ Account No: :__________________ Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 108% Original Issue Discount Senior Secured Convertible Note Debenture due February 26January 1, 2020 2017 of OncBioMune PharmaceuticalsPFO Global, Inc., a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: __________________ Account No: __________________ Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal and interest under the 1015% Senior OID Convertible Note Promissory Notes due February 26May __, 2020 2022 of OncBioMune PharmaceuticalsmPhase Technologies, Inc., a Nevada corporation Inc. (the “Company”), into shares of its common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: :______________________________________ Principal Amount of Note to be Converted: :________________________ Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker No: :___________________ Account NoSignature Name Delivery Instructions: _________________Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Original Issue Discount Senior Secured Convertible Note Debenture due February 26May 16, 2020 2016 of OncBioMune PharmaceuticalsLegend Oil and Gas, Inc.Ltd., a Nevada Colorado corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: Address for Delivery of Common Stock Certificates: Or DWAC Instructions: Broker No: :______________________________ Account No: :_____________________________ Schedule 1

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Original Issue Discount Senior Secured Convertible Note Debenture due February 26October __, 2020 2014 of OncBioMune PharmaceuticalsWindstream Technologies, Inc., a Nevada Wyoming corporation (the ““ Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this NoteDebenture, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note Debenture to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker No: __________________ Account No: APPENDIX A Amortization Schedule Amortization Payments Cash (30% Premium) Common Stock First Payment (4/__/15) [6 months from original issuance date] $ 160,361.73 $ 123,355.18 Second Payment (5/1/15) $ 90,871.65 $ 69,901.27 Third Payment (5/15/15) $ 90,871.65 $ 69,901.27 Fourth payment (6/1/15) $ 80,180.87 $ 61,677.59 Fifth Payment (6/15/15) $ 80,180.87 $ 61,677.59 Sixth Payment (7/1/15) $ 23,519.73 $ 18,092.10 Seventh Payment (7/15/15) $ 23,519.73 $ 18,092.10 Eighth Payment (8/1/15) $ 21,381.57 $ 16,447.36 Ninth Payment (8/15/15) $ 21,381.57 $ 16,447.36 Tenth Payment (9/1/15) $ 58,799.30 $ 45,230.23 Eleventh Payment (9/15/15) $ 58,799.30 $ 45,230.23 Twelfth Payment (10/__/15) [12 months from original issuance date] $ 42,763.14 $ 32,894.72 Schedule 1 CONVERSION SCHEDULE This Original Issue Discount Senior Secured Convertible Debenture due on October _________________, 2014 in the original principal amount of $3,520,000 is issued by Windstream Technologies, Inc., a Wyoming corporation. This Conversion Schedule reflects conversions made under Section 4 of the above referenced Debenture. Dated: Date of Conversion (or for first entry, Original Issue Date) Amount of Conversion Aggregate Principal Amount Remaining Subsequent to Conversion (or original Principal Amount) Company Attest

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Convertible Note due February 26July 18, 2020 2017 of OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: Name: DWAC Instructions: Broker No: :___________________ Account No: :_____________________ Schedule 1

NOTICE OF CONVERSION. (To be Executed by the Registered Holder in order to convert shares of Preferred Stock) The undersigned hereby elects to convert principal under the 10% Senior number of shares of Series D Convertible Note due February 26Preferred Stock indicated below, 2020 into shares of OncBioMune Pharmaceuticalscommon stock, par value $.00001 per share (the “Common Stock”), of BioNeutral Group, Inc., a Nevada corporation (the “Company”), into shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder Holder for any conversion, except for such transfer taxes, if any. By the delivery of tendering this Notice of Conversion Conversion, the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees hereby covenants to comply with the prospectus delivery requirements under the Securities Act of 1933, as amended, applicable securities laws in connection to it with any transfer respect to resales of the aforesaid shares of Common StockStock issuable upon the conversion requested hereby pursuant to a registration statement and, in connection therewith, covenants that, unless otherwise specified below, such shares have been or are intended to be sold in ordinary brokerage transactions. Conversion calculations: Date to Effect Conversion: Principal Amount Conversion Number of Note shares of Preferred Stock owned prior to Conversion Number of shares of Preferred Stock to be Converted: Payment Converted Stated Value of Interest in Common shares of Preferred Stock __ yes __ no If yes, $_____ of Interest Accrued on Account of Conversion at Issue. to be Converted Number of shares of Common Stock to be issuedIssued Applicable Conversion Price Number of shares of Preferred Stock subsequent to Conversion Signature Name Address Accepted and Agreed: Signature: Name: DWAC Instructions: Broker No: BioNeutral Group, Inc. By:_____________________________________ Account NoName: _________________Title:

NOTICE OF CONVERSION. The undersigned hereby elects to convert the principal under the 10% Senior Secured Convertible Promissory Note due February 26May 9, 2020 2025 (the “Note”) of OncBioMune PharmaceuticalsRxxx’x, Inc.Inc, a Nevada Delaware corporation (the “CompanyBorrower”), into shares of common stock stock, par value $0.0001 per share (the “Common Stock”), of the Company Borrower according to the conditions hereof, as of the date written below. If shares of Common Stock are Capitalized terms used but not otherwise defined herein shall have the meanings assigned to be issued such terms in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if anyNotes. By the delivery of this Notice of Conversion Conversion, except as otherwise noted below, the undersigned represents and warrants to the Company Borrower that its ownership of the Common Stock issuable in connection with this conversion (including as part of any Interest Make-Whole Payment) does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d5(b) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common StockNote. Conversion calculations: Date to Effect ConversionDate: Principal Amount of Note to be Converted: Payment DTC Account Delivery Instructions: Wire Instructions (for cash payments): Other Matters: Updated Conversion/PIK Schedule Attached. [______________] By: Name: Title: Dated: ANNEX B ACKNOWLEDGMENT OF CONVERSION Reference is made to the Secured Convertible Promissory Notes due May 09, 2025 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Notes”), issued by Rxxx’x, Inc., a Delaware corporation (the “Borrower”), and Wilmington Savings Fund Society, FSB, as holder representative and collateral agent. Capitalized terms used but not otherwise defined herein shall have the meanings assigned to such terms in the Notes. The Borrower hereby (a) acknowledges the Notice of Interest in Conversion dated [___], (b) certifies that the shares of Common Stock [are][are not] eligible to be resold by the Holder either (i) pursuant to Rule 144 (subject to the Holder’s execution and delivery to the Borrower of a customary Rule 144 representation letter) or (ii) an effective and available registration statement covering such shares of Common Stock and (c) hereby directs __ yes __ no If yes, $_______________ of Interest Accrued on Account of Conversion at Issue. Number to issue the above indicated number of shares of Common Stock in accordance with the Transfer Agent Instructions dated _____________, 20__ from the Borrower and acknowledged and agreed to be issued: Signature: Name: DWAC Instructions: Broker No: by __________________ Account _______. RXXX’X, INC., as Borrower a Delaware corporation By: Name: Title: ANNEX C FUNDAMENTAL CHANGE REPURCHASE NOTICE RXXX’X INC. 10.00% Secured Convertible Promissory Notes due 2025 Subject to the terms of the Notes, by executing and delivering this Fundamental Change Repurchase Notice, the undersigned Holder of the Note identified below is exercising its Fundamental Change Repurchase Right with respect to (check one): ☐ the entire principal amount of ☐ $ __________* aggregate principal amount of the Note identified by Certificate No: . _________________. The undersigned acknowledges that this Note, duly endorsed for transfer, must be delivered to the Paying Agent before the Fundamental Change Repurchase Price will be paid. Date: (Legal Name of Holder) By: Name: Title: SCHEDULE 1 CONVERSION/PIK SCHEDULE8 This Conversion/PIK Schedule is part of, and reflects conversions made under Section 4 of and PIK Interest paid on, the Secured Convertible Promissory Note, due on May 9, 2025, in the original principal amount of $[●]9 issued by Rxxx’x, Inc., a Delaware corporation. Date of Conversion, Amortization Payment or PIK Interest Payment (or for first entry, Original Issue Date) Amount of Conversion, Amortization or PIK Interest Aggregate Principal Amount Remaining Subsequent to Conversion, Amortization or PIK Interest(or original Principal Amount) Borrower Attest

NOTICE OF CONVERSION. The undersigned hereby elects to convert principal under the 10% Senior Secured Subordinated Convertible Note Promissory Note, due February 2611, 2020 2022 of OncBioMune PharmaceuticalsBergio International, Inc.Inc.., a Nevada Wyoming corporation (the “Company”), into shares of common stock stock, $0.00001 par value per share (the “Common Stock”), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any. By the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act. The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock. Conversion calculations: Date to Effect Conversion: Principal Amount of Note to be Converted: Payment of Interest in Common Stock _____ yes _____ no If yes, $___________ of Interest Accrued on Account of Conversion at Issue. Number of shares of Common Stock to be issued: Signature: ____________________________ Name: DWAC Instructions: Broker No: _______________________________ Account NoDelivery Instructions: ___________________ EXECUTION COPY ANNEX B ACKNOWLEDGMENT OF CONVERSION The Company hereby (a) acknowledges this Notice of Conversion, (b) certifies that the above indicated number of shares of Common Stock [are][are not] eligible to be resold by the Holder either (i) pursuant to Rule 144 (subject to the Holder’s execution and delivery to the Company of a customary Rule 144 representation letter) or (ii) an effective and available registration statement covering such shares of Common Stock and (c) hereby directs Empire Stock Transfer, Xxx.xx issue the above indicated number of shares of Common Stock in accordance with the Transfer Agent Instructions dated February 11, 2021 from the Company and acknowledged and agreed to by Empire Stock Transfer, Inc. BERGIO INTERNATIONAL, INC. By: _______________________________________ Xxxxx Xxxxxxx, Chief Executive Officer EXECUTION COPY SCHEDULE 1 CONVERSION SCHEDULE This Conversion Schedule is part of, and reflects conversions made under Section 4 of, the 10% Secured Subordinated Convertible Promissory Note, due on February 11, 2022, in the original principal amount of $1,512,500.00 issued by Bergio International, Inc., a Wyoming corporation. Dated:_____________________ Date of Conversion (or for first entry, Original Issue Date) Amount of Conversion Aggregate Principal Amount Remaining Subsequent to Conversion (or original Principal Amount) Company Attest EXECUTION COPY SCHEDULE 6(a) OPTIONAL REDEMPTION AMOUNT Subject to compliance with Section 6(a) of the Convertible Secured Subordinated Promissory Note dated February 11, 2021, and subject to the Holder’s right under Section 6(c) to convert all or any portion of the Note, including outstanding principal, accrued interest and penalties, as applicable, for Seventy-Two (72) Hours following receipt of the Company’s Optional Redemption Notice, the Company may redeem any portion of the principal amount of this Note, any accrued and unpaid interest, and any other amounts due under this Note in accordance with the following formulae: if the Company exercises its right to redeem the Note, the Company shall make payment to the Holder of (i) an amount in cash equal to the product of (x) the sum of the principal amount of this Note and any accrued and unpaid interest and (y) 110%, if such voluntary redemption occurs on or before April 11, 20211, (ii) an amount in cash equal to the product of (x) the sum of the principal amount of this Note and any accrued and unpaid interest and (y) 115%, if such voluntary prepayment occurs after April 11, 2021 and before May 11, 20212, (iii) an amount in cash equal to the product of (x) the sum of the principal amount of this Note and any accrued and unpaid interest and (y) 120%, if such voluntary prepayment occurs after May 11, 2021 and before June 10, 20213, (iv) an amount in cash equal to the product of (x) the sum of the principal amount of this Note and any accrued and unpaid interest and (y) 125%, if such voluntary prepayment occurs after June 10, 2021 and before July 10, 20214, (v) an amount in cash equal to the product of (x) the sum of the principal amount of this Note and any accrued and unpaid interest and (y) 130%, if such voluntary prepayment occurs after July 10, 2021 and before August 10, 20215, and (vi) an amount in cash equal to the product of (x) the sum of the principal amount of this Note and any accrued and unpaid interest and (y) 135%, if such voluntary prepayment occurs after August 10, 20216 and before the Maturity Date. The above Optional Redemption Amount applies only to the Convertible Secured Subordinated Promissory Note dated February 11, 2021, and the Warrant dated February 11, 2021 is not redeemable by the Company. _____________________________________________________________________ 1 NTD: within 60 days after the Original Issue Date. 2 NTD: between the 61st day and the 90th day after the Original Issue Date. 3 NTD: between the 91st day and the 120th day after the Original Issue Date. 4 NTD: between the 121st day and the 150th day after the Original Issue Date. 5 NTD: between the 151st day and the 180th day after the Original Issue Date.